Brought to you by 
AstraZeneca pays $35mm up front for rights to Ardelyx's NH3 inhibitors; deal ends
04 Jun 2015
Executive Summary
Ardelyx Inc. (developing therapeutics that target gut transporters and receptors related to cardiovascular, renal, and gastrointestinal diseases) has granted AstraZeneca PLC exclusive global rights to its sodium-hydrogen exchange 3 (NHE3) inhibitor program, including lead compound RDX5791, which is in Phase II trials for complications of end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca pays $35mm up front for rights to Ardelyx's NH3 inhibitors; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice